Vertex Pharmaceuticals Inc (VRTX) stock
VRTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 15/3028% above fair value
$547.03−0.86 (-0.16%)
Close on Nov 11, 2026Market cap $138.65BP/E 31.8Yield –
Vertex Pharmaceuticals gross margin
Gross margin is gross profit as a percentage of revenue.
Vertex Pharmaceuticals's gross margin for the twelve months ending Jun 30, 2026 was 86.0%. For fiscal 2025 it was 86.2%, against 86.1% the year before. The highest annual figure on record is 100.0% in fiscal 2010.
Annual gross margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 86.2% | +0.1 |
| FY2024 | Dec 31, 2024 | 86.1% | −1.1 |
| FY2023 | Dec 31, 2023 | 87.2% | −0.7 |
| FY2022 | Dec 31, 2022 | 87.9% | −0.2 |
| FY2021 | Dec 31, 2021 | 88.1% | −0.1 |
| FY2020 | Dec 31, 2020 | 88.1% | +1.3 |
| FY2019 | Dec 31, 2019 | 86.8% | +0.3 |
| FY2018 | Dec 31, 2018 | 86.6% | −2.4 |
| FY2017 | Dec 31, 2017 | 88.9% | +1.3 |
| FY2016 | Dec 31, 2016 | 87.6% | −1.0 |
| FY2015 | Dec 31, 2015 | 88.7% | −4.5 |
| FY2014 | Dec 31, 2014 | 93.2% | +0.5 |
| FY2013 | Dec 31, 2013 | 92.7% | +8.2 |
| FY2012 | Dec 31, 2012 | 84.5% | −11.0 |
| FY2011 | Dec 31, 2011 | 95.5% | −4.5 |
| FY2010 | Dec 31, 2010 | 100.0% | – |
Quarterly gross margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | 85.3% | −0.9 |
| Q1 FY2026 | Mar 31, 2026 | 86.8% | −0.0 |
| Q4 FY2025 | Dec 31, 2025 | 85.4% | −0.1 |
| Q3 FY2025 | Sep 30, 2025 | 86.5% | +0.7 |
| Q2 FY2025 | Jun 30, 2025 | 86.3% | +0.3 |
| Q1 FY2025 | Mar 31, 2025 | 86.9% | −0.4 |
| Q4 FY2024 | Dec 31, 2024 | 85.5% | +0.1 |
| Q3 FY2024 | Sep 30, 2024 | 85.8% | −1.3 |
| Q2 FY2024 | Jun 30, 2024 | 85.9% | −1.7 |
| Q1 FY2024 | Mar 31, 2024 | 87.3% | −1.5 |
| Q4 FY2023 | Dec 31, 2023 | 85.4% | −2.3 |
| Q3 FY2023 | Sep 30, 2023 | 87.2% | −0.4 |
| Q2 FY2023 | Jun 30, 2023 | 87.6% | −0.5 |
| Q1 FY2023 | Mar 31, 2023 | 88.8% | +0.5 |
| Q4 FY2022 | Dec 31, 2022 | 87.7% | −0.4 |
| Q3 FY2022 | Sep 30, 2022 | 87.6% | −0.5 |
| Q2 FY2022 | Jun 30, 2022 | 88.1% | +0.8 |
| Q1 FY2022 | Mar 31, 2022 | 88.3% | −0.6 |
| Q4 FY2021 | Dec 31, 2021 | 88.1% | +0.5 |
| Q3 FY2021 | Sep 30, 2021 | 88.1% | +0.2 |
| Q2 FY2021 | Jun 30, 2021 | 87.3% | −0.6 |
| Q1 FY2021 | Mar 31, 2021 | 88.8% | −0.4 |
| Q4 FY2020 | Dec 31, 2020 | 87.5% | +0.6 |
| Q3 FY2020 | Sep 30, 2020 | 87.9% | +1.8 |
| Q2 FY2020 | Jun 30, 2020 | 87.9% | +2.3 |
| Q1 FY2020 | Mar 31, 2020 | 89.3% | +0.4 |
| Q4 FY2019 | Dec 31, 2019 | 86.9% | +1.0 |
| Q3 FY2019 | Sep 30, 2019 | 86.1% | +0.3 |
| Q2 FY2019 | Jun 30, 2019 | 85.6% | −0.5 |
| Q1 FY2019 | Mar 31, 2019 | 88.9% | +0.1 |
| Q4 FY2018 | Dec 31, 2018 | 85.9% | −1.2 |
| Q3 FY2018 | Sep 30, 2018 | 85.8% | −1.6 |
| Q2 FY2018 | Jun 30, 2018 | 86.1% | −0.8 |
| Q1 FY2018 | Mar 31, 2018 | 88.8% | −4.6 |
| Q4 FY2017 | Dec 31, 2017 | 87.1% | +0.1 |
| Q3 FY2017 | Sep 30, 2017 | 87.4% | +0.3 |
| Q2 FY2017 | Jun 30, 2017 | 86.9% | – |
| Q1 FY2017 | Mar 31, 2017 | 93.4% | – |
| Q4 FY2016 | Dec 31, 2016 | 87.0% | – |
| Q3 FY2016 | Sep 30, 2016 | 87.1% | – |
See a number that looks wrong?